nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—CYP19A1—esophageal cancer	0.451	0.719	CbGaD
Mefloquine—ABCB1—esophageal cancer	0.176	0.281	CbGaD
Mefloquine—BCHE—Cisplatin—esophageal cancer	0.0522	0.705	CbGbCtD
Mefloquine—ABCB1—Cisplatin—esophageal cancer	0.0132	0.179	CbGbCtD
Mefloquine—BCHE—diaphragm—esophageal cancer	0.0101	0.161	CbGeAlD
Mefloquine—HBA2—exocrine gland—esophageal cancer	0.0101	0.161	CbGeAlD
Mefloquine—ABCB1—Methotrexate—esophageal cancer	0.0086	0.116	CbGbCtD
Mefloquine—HBA2—neck—esophageal cancer	0.00643	0.103	CbGeAlD
Mefloquine—HBA2—epithelium—esophageal cancer	0.00437	0.0699	CbGeAlD
Mefloquine—HBA2—smooth muscle tissue—esophageal cancer	0.00422	0.0674	CbGeAlD
Mefloquine—HBA1—digestive system—esophageal cancer	0.00363	0.0579	CbGeAlD
Mefloquine—HBA2—digestive system—esophageal cancer	0.00333	0.0532	CbGeAlD
Mefloquine—HBA1—lung—esophageal cancer	0.00303	0.0484	CbGeAlD
Mefloquine—HBA2—lung—esophageal cancer	0.00278	0.0444	CbGeAlD
Mefloquine—Haemolysis—Cisplatin—esophageal cancer	0.00233	0.0369	CcSEcCtD
Mefloquine—HBA1—lymph node—esophageal cancer	0.00207	0.0331	CbGeAlD
Mefloquine—Peripheral sensory neuropathy—Capecitabine—esophageal cancer	0.00191	0.0303	CcSEcCtD
Mefloquine—HBA2—lymph node—esophageal cancer	0.0019	0.0304	CbGeAlD
Mefloquine—Panic attack—Capecitabine—esophageal cancer	0.00147	0.0233	CcSEcCtD
Mefloquine—ADORA1—lung—esophageal cancer	0.00125	0.02	CbGeAlD
Mefloquine—Retinal disorder—Methotrexate—esophageal cancer	0.00114	0.0181	CcSEcCtD
Mefloquine—Haematocrit decreased—Methotrexate—esophageal cancer	0.00109	0.0173	CcSEcCtD
Mefloquine—Balance disorder—Capecitabine—esophageal cancer	0.001	0.0158	CcSEcCtD
Mefloquine—BCHE—bronchus—esophageal cancer	0.000946	0.0151	CbGeAlD
Mefloquine—BCHE—smooth muscle tissue—esophageal cancer	0.000925	0.0148	CbGeAlD
Mefloquine—ADORA1—lymph node—esophageal cancer	0.000854	0.0137	CbGeAlD
Mefloquine—Encephalopathy—Capecitabine—esophageal cancer	0.000852	0.0135	CcSEcCtD
Mefloquine—BCHE—trachea—esophageal cancer	0.000849	0.0136	CbGeAlD
Mefloquine—ACHE—lymph node—esophageal cancer	0.000849	0.0136	CbGeAlD
Mefloquine—Appetite absent—Methotrexate—esophageal cancer	0.000819	0.013	CcSEcCtD
Mefloquine—Hearing impaired—Cisplatin—esophageal cancer	0.00078	0.0123	CcSEcCtD
Mefloquine—Blister—Capecitabine—esophageal cancer	0.000759	0.012	CcSEcCtD
Mefloquine—Hepatocellular injury—Cisplatin—esophageal cancer	0.000742	0.0118	CcSEcCtD
Mefloquine—BCHE—digestive system—esophageal cancer	0.000731	0.0117	CbGeAlD
Mefloquine—Body temperature increased—Carboplatin—esophageal cancer	0.000714	0.0113	CcSEcCtD
Mefloquine—Memory impairment—Capecitabine—esophageal cancer	0.000697	0.011	CcSEcCtD
Mefloquine—Neuropathy—Cisplatin—esophageal cancer	0.000697	0.011	CcSEcCtD
Mefloquine—Extrasystoles—Capecitabine—esophageal cancer	0.00065	0.0103	CcSEcCtD
Mefloquine—Encephalopathy—Methotrexate—esophageal cancer	0.000635	0.01	CcSEcCtD
Mefloquine—BCHE—lung—esophageal cancer	0.00061	0.00975	CbGeAlD
Mefloquine—Deafness—Cisplatin—esophageal cancer	0.000602	0.00953	CcSEcCtD
Mefloquine—Liver disorder—Methotrexate—esophageal cancer	0.000598	0.00946	CcSEcCtD
Mefloquine—CYP19A1—lymph node—esophageal cancer	0.000579	0.00926	CbGeAlD
Mefloquine—Hearing impaired—Capecitabine—esophageal cancer	0.000575	0.0091	CcSEcCtD
Mefloquine—Cataract—Capecitabine—esophageal cancer	0.000575	0.0091	CcSEcCtD
Mefloquine—Coordination abnormal—Capecitabine—esophageal cancer	0.000557	0.00882	CcSEcCtD
Mefloquine—Influenza like illness—Capecitabine—esophageal cancer	0.000531	0.00841	CcSEcCtD
Mefloquine—Irritability—Cisplatin—esophageal cancer	0.000514	0.00814	CcSEcCtD
Mefloquine—Neuropathy—Capecitabine—esophageal cancer	0.000514	0.00813	CcSEcCtD
Mefloquine—CYP3A4—digestive system—esophageal cancer	0.000492	0.00786	CbGeAlD
Mefloquine—Cramp muscle—Cisplatin—esophageal cancer	0.000485	0.00768	CcSEcCtD
Mefloquine—CYP2D6—digestive system—esophageal cancer	0.000484	0.00774	CbGeAlD
Mefloquine—Sleep disorder—Capecitabine—esophageal cancer	0.000459	0.00726	CcSEcCtD
Mefloquine—ABCB1—epithelium—esophageal cancer	0.000458	0.00732	CbGeAlD
Mefloquine—Deafness—Capecitabine—esophageal cancer	0.000444	0.00703	CcSEcCtD
Mefloquine—Hepatic failure—Capecitabine—esophageal cancer	0.000442	0.007	CcSEcCtD
Mefloquine—BCHE—lymph node—esophageal cancer	0.000417	0.00667	CbGeAlD
Mefloquine—Dermatitis bullous—Capecitabine—esophageal cancer	0.000416	0.00658	CcSEcCtD
Mefloquine—Renal failure—Cisplatin—esophageal cancer	0.000408	0.00646	CcSEcCtD
Mefloquine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000407	0.00644	CcSEcCtD
Mefloquine—ABCB1—trachea—esophageal cancer	0.000405	0.00647	CbGeAlD
Mefloquine—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000393	0.00622	CcSEcCtD
Mefloquine—Aplastic anaemia—Methotrexate—esophageal cancer	0.000382	0.00605	CcSEcCtD
Mefloquine—Bradycardia—Cisplatin—esophageal cancer	0.000379	0.00601	CcSEcCtD
Mefloquine—Irritability—Capecitabine—esophageal cancer	0.000379	0.006	CcSEcCtD
Mefloquine—Mood swings—Capecitabine—esophageal cancer	0.000376	0.00596	CcSEcCtD
Mefloquine—Ataxia—Capecitabine—esophageal cancer	0.000373	0.00591	CcSEcCtD
Mefloquine—Coma—Methotrexate—esophageal cancer	0.000372	0.00589	CcSEcCtD
Mefloquine—Connective tissue disorder—Cisplatin—esophageal cancer	0.000366	0.0058	CcSEcCtD
Mefloquine—Visual impairment—Cisplatin—esophageal cancer	0.000359	0.00569	CcSEcCtD
Mefloquine—Muscular weakness—Capecitabine—esophageal cancer	0.00035	0.00555	CcSEcCtD
Mefloquine—Eye disorder—Cisplatin—esophageal cancer	0.000348	0.00551	CcSEcCtD
Mefloquine—ABCB1—digestive system—esophageal cancer	0.000348	0.00557	CbGeAlD
Mefloquine—Tinnitus—Cisplatin—esophageal cancer	0.000348	0.0055	CcSEcCtD
Mefloquine—Flushing—Cisplatin—esophageal cancer	0.000346	0.00548	CcSEcCtD
Mefloquine—Cardiac disorder—Cisplatin—esophageal cancer	0.000346	0.00548	CcSEcCtD
Mefloquine—Mediastinal disorder—Cisplatin—esophageal cancer	0.000336	0.00532	CcSEcCtD
Mefloquine—Alopecia—Cisplatin—esophageal cancer	0.000329	0.00521	CcSEcCtD
Mefloquine—Hepatic failure—Methotrexate—esophageal cancer	0.000329	0.00521	CcSEcCtD
Mefloquine—Erythema—Cisplatin—esophageal cancer	0.000324	0.00514	CcSEcCtD
Mefloquine—Malnutrition—Cisplatin—esophageal cancer	0.000324	0.00514	CcSEcCtD
Mefloquine—Visual disturbance—Methotrexate—esophageal cancer	0.000312	0.00494	CcSEcCtD
Mefloquine—Muscle spasms—Cisplatin—esophageal cancer	0.000312	0.00494	CcSEcCtD
Mefloquine—Pneumonia—Capecitabine—esophageal cancer	0.000308	0.00487	CcSEcCtD
Mefloquine—Vision blurred—Cisplatin—esophageal cancer	0.000306	0.00484	CcSEcCtD
Mefloquine—Tremor—Cisplatin—esophageal cancer	0.000304	0.00481	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000303	0.0048	CcSEcCtD
Mefloquine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000301	0.00477	CcSEcCtD
Mefloquine—Renal failure—Capecitabine—esophageal cancer	0.000301	0.00476	CcSEcCtD
Mefloquine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.0003	0.00475	CcSEcCtD
Mefloquine—Malaise—Cisplatin—esophageal cancer	0.000293	0.00463	CcSEcCtD
Mefloquine—ABCB1—lung—esophageal cancer	0.000291	0.00465	CbGeAlD
Mefloquine—Leukopenia—Cisplatin—esophageal cancer	0.00029	0.0046	CcSEcCtD
Mefloquine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000289	0.00458	CcSEcCtD
Mefloquine—Agranulocytosis—Capecitabine—esophageal cancer	0.000286	0.00452	CcSEcCtD
Mefloquine—Irritability—Methotrexate—esophageal cancer	0.000282	0.00447	CcSEcCtD
Mefloquine—Convulsion—Cisplatin—esophageal cancer	0.000281	0.00445	CcSEcCtD
Mefloquine—Mood swings—Methotrexate—esophageal cancer	0.00028	0.00443	CcSEcCtD
Mefloquine—Bradycardia—Capecitabine—esophageal cancer	0.00028	0.00443	CcSEcCtD
Mefloquine—Ataxia—Methotrexate—esophageal cancer	0.000278	0.0044	CcSEcCtD
Mefloquine—Myalgia—Cisplatin—esophageal cancer	0.000276	0.00437	CcSEcCtD
Mefloquine—Anxiety—Cisplatin—esophageal cancer	0.000275	0.00436	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000274	0.00434	CcSEcCtD
Mefloquine—Discomfort—Cisplatin—esophageal cancer	0.000273	0.00432	CcSEcCtD
Mefloquine—Connective tissue disorder—Capecitabine—esophageal cancer	0.00027	0.00427	CcSEcCtD
Mefloquine—Oedema—Cisplatin—esophageal cancer	0.000265	0.00419	CcSEcCtD
Mefloquine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000265	0.00419	CcSEcCtD
Mefloquine—Visual impairment—Capecitabine—esophageal cancer	0.000265	0.00419	CcSEcCtD
Mefloquine—Erythema multiforme—Capecitabine—esophageal cancer	0.00026	0.00411	CcSEcCtD
Mefloquine—Nervous system disorder—Cisplatin—esophageal cancer	0.00026	0.00411	CcSEcCtD
Mefloquine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000259	0.0041	CcSEcCtD
Mefloquine—Tachycardia—Cisplatin—esophageal cancer	0.000258	0.00409	CcSEcCtD
Mefloquine—Skin disorder—Cisplatin—esophageal cancer	0.000257	0.00407	CcSEcCtD
Mefloquine—Eye disorder—Capecitabine—esophageal cancer	0.000257	0.00406	CcSEcCtD
Mefloquine—Tinnitus—Capecitabine—esophageal cancer	0.000256	0.00406	CcSEcCtD
Mefloquine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000256	0.00405	CcSEcCtD
Mefloquine—Flushing—Capecitabine—esophageal cancer	0.000255	0.00404	CcSEcCtD
Mefloquine—Cardiac disorder—Capecitabine—esophageal cancer	0.000255	0.00404	CcSEcCtD
Mefloquine—Angiopathy—Capecitabine—esophageal cancer	0.000249	0.00395	CcSEcCtD
Mefloquine—Mediastinal disorder—Capecitabine—esophageal cancer	0.000248	0.00392	CcSEcCtD
Mefloquine—Hypotension—Cisplatin—esophageal cancer	0.000247	0.00392	CcSEcCtD
Mefloquine—Chills—Capecitabine—esophageal cancer	0.000247	0.0039	CcSEcCtD
Mefloquine—Alopecia—Capecitabine—esophageal cancer	0.000243	0.00384	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000241	0.00382	CcSEcCtD
Mefloquine—Mental disorder—Capecitabine—esophageal cancer	0.000241	0.00381	CcSEcCtD
Mefloquine—Malnutrition—Capecitabine—esophageal cancer	0.000239	0.00379	CcSEcCtD
Mefloquine—Erythema—Capecitabine—esophageal cancer	0.000239	0.00379	CcSEcCtD
Mefloquine—Paraesthesia—Cisplatin—esophageal cancer	0.000238	0.00376	CcSEcCtD
Mefloquine—Dyspnoea—Cisplatin—esophageal cancer	0.000236	0.00374	CcSEcCtD
Mefloquine—Decreased appetite—Cisplatin—esophageal cancer	0.00023	0.00364	CcSEcCtD
Mefloquine—Muscle spasms—Capecitabine—esophageal cancer	0.00023	0.00364	CcSEcCtD
Mefloquine—Pneumonia—Methotrexate—esophageal cancer	0.000229	0.00363	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000229	0.00362	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000226	0.00358	CcSEcCtD
Mefloquine—Vision blurred—Capecitabine—esophageal cancer	0.000225	0.00357	CcSEcCtD
Mefloquine—Tremor—Capecitabine—esophageal cancer	0.000224	0.00355	CcSEcCtD
Mefloquine—Renal failure—Methotrexate—esophageal cancer	0.000224	0.00355	CcSEcCtD
Mefloquine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000222	0.00351	CcSEcCtD
Mefloquine—Sweating—Methotrexate—esophageal cancer	0.000218	0.00346	CcSEcCtD
Mefloquine—Feeling abnormal—Cisplatin—esophageal cancer	0.000218	0.00345	CcSEcCtD
Mefloquine—Malaise—Capecitabine—esophageal cancer	0.000216	0.00341	CcSEcCtD
Mefloquine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000215	0.00341	CcSEcCtD
Mefloquine—Vertigo—Capecitabine—esophageal cancer	0.000215	0.0034	CcSEcCtD
Mefloquine—Syncope—Capecitabine—esophageal cancer	0.000214	0.0034	CcSEcCtD
Mefloquine—Leukopenia—Capecitabine—esophageal cancer	0.000214	0.00339	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—esophageal cancer	0.000213	0.00337	CcSEcCtD
Mefloquine—Palpitations—Capecitabine—esophageal cancer	0.000211	0.00335	CcSEcCtD
Mefloquine—Loss of consciousness—Capecitabine—esophageal cancer	0.00021	0.00333	CcSEcCtD
Mefloquine—Body temperature increased—Cisplatin—esophageal cancer	0.000209	0.00331	CcSEcCtD
Mefloquine—Hypertension—Capecitabine—esophageal cancer	0.000207	0.00327	CcSEcCtD
Mefloquine—Myalgia—Capecitabine—esophageal cancer	0.000204	0.00322	CcSEcCtD
Mefloquine—Arthralgia—Capecitabine—esophageal cancer	0.000204	0.00322	CcSEcCtD
Mefloquine—Chest pain—Capecitabine—esophageal cancer	0.000204	0.00322	CcSEcCtD
Mefloquine—Anxiety—Capecitabine—esophageal cancer	0.000203	0.00321	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000202	0.0032	CcSEcCtD
Mefloquine—Discomfort—Capecitabine—esophageal cancer	0.000201	0.00318	CcSEcCtD
Mefloquine—ABCB1—lymph node—esophageal cancer	0.000199	0.00318	CbGeAlD
Mefloquine—Visual impairment—Methotrexate—esophageal cancer	0.000197	0.00312	CcSEcCtD
Mefloquine—Confusional state—Capecitabine—esophageal cancer	0.000197	0.00312	CcSEcCtD
Mefloquine—Oedema—Capecitabine—esophageal cancer	0.000195	0.00309	CcSEcCtD
Mefloquine—Hypersensitivity—Cisplatin—esophageal cancer	0.000195	0.00309	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—esophageal cancer	0.000193	0.00306	CcSEcCtD
Mefloquine—Shock—Capecitabine—esophageal cancer	0.000192	0.00304	CcSEcCtD
Mefloquine—Nervous system disorder—Capecitabine—esophageal cancer	0.000191	0.00303	CcSEcCtD
Mefloquine—Eye disorder—Methotrexate—esophageal cancer	0.000191	0.00303	CcSEcCtD
Mefloquine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000191	0.00303	CcSEcCtD
Mefloquine—Tinnitus—Methotrexate—esophageal cancer	0.000191	0.00302	CcSEcCtD
Mefloquine—Tachycardia—Capecitabine—esophageal cancer	0.000191	0.00302	CcSEcCtD
Mefloquine—Asthenia—Cisplatin—esophageal cancer	0.00019	0.00301	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—esophageal cancer	0.00019	0.003	CcSEcCtD
Mefloquine—Skin disorder—Capecitabine—esophageal cancer	0.00019	0.003	CcSEcCtD
Mefloquine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000189	0.00299	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—esophageal cancer	0.000186	0.00294	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—esophageal cancer	0.000184	0.00292	CcSEcCtD
Mefloquine—Chills—Methotrexate—esophageal cancer	0.000184	0.00291	CcSEcCtD
Mefloquine—Hypotension—Capecitabine—esophageal cancer	0.000182	0.00289	CcSEcCtD
Mefloquine—Diarrhoea—Cisplatin—esophageal cancer	0.000181	0.00287	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—esophageal cancer	0.000181	0.00286	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—esophageal cancer	0.000179	0.00284	CcSEcCtD
Mefloquine—Erythema—Methotrexate—esophageal cancer	0.000178	0.00282	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—esophageal cancer	0.000178	0.00282	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000178	0.00282	CcSEcCtD
Mefloquine—Insomnia—Capecitabine—esophageal cancer	0.000177	0.00279	CcSEcCtD
Mefloquine—Paraesthesia—Capecitabine—esophageal cancer	0.000175	0.00277	CcSEcCtD
Mefloquine—Dyspnoea—Capecitabine—esophageal cancer	0.000174	0.00275	CcSEcCtD
Mefloquine—Dyspepsia—Capecitabine—esophageal cancer	0.000172	0.00272	CcSEcCtD
Mefloquine—Decreased appetite—Capecitabine—esophageal cancer	0.00017	0.00269	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000169	0.00267	CcSEcCtD
Mefloquine—Vomiting—Cisplatin—esophageal cancer	0.000168	0.00267	CcSEcCtD
Mefloquine—Fatigue—Capecitabine—esophageal cancer	0.000168	0.00266	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—esophageal cancer	0.000168	0.00266	CcSEcCtD
Mefloquine—Rash—Cisplatin—esophageal cancer	0.000167	0.00264	CcSEcCtD
Mefloquine—Dermatitis—Cisplatin—esophageal cancer	0.000167	0.00264	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000165	0.00262	CcSEcCtD
Mefloquine—Feeling abnormal—Capecitabine—esophageal cancer	0.000161	0.00255	CcSEcCtD
Mefloquine—Malaise—Methotrexate—esophageal cancer	0.000161	0.00254	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—esophageal cancer	0.00016	0.00253	CcSEcCtD
Mefloquine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00016	0.00253	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—esophageal cancer	0.000159	0.00252	CcSEcCtD
Mefloquine—Nausea—Cisplatin—esophageal cancer	0.000157	0.00249	CcSEcCtD
Mefloquine—Urticaria—Capecitabine—esophageal cancer	0.000155	0.00245	CcSEcCtD
Mefloquine—Abdominal pain—Capecitabine—esophageal cancer	0.000154	0.00244	CcSEcCtD
Mefloquine—Body temperature increased—Capecitabine—esophageal cancer	0.000154	0.00244	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—esophageal cancer	0.000154	0.00244	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—esophageal cancer	0.000152	0.0024	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—esophageal cancer	0.000152	0.0024	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—esophageal cancer	0.000152	0.0024	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000151	0.00238	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—esophageal cancer	0.00015	0.00237	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—esophageal cancer	0.000147	0.00232	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000145	0.0023	CcSEcCtD
Mefloquine—Hypersensitivity—Capecitabine—esophageal cancer	0.000144	0.00228	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—esophageal cancer	0.000143	0.00226	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000142	0.00225	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—esophageal cancer	0.000141	0.00223	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—esophageal cancer	0.00014	0.00222	CcSEcCtD
Mefloquine—Asthenia—Capecitabine—esophageal cancer	0.00014	0.00222	CcSEcCtD
Mefloquine—Pruritus—Capecitabine—esophageal cancer	0.000138	0.00219	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—esophageal cancer	0.000136	0.00215	CcSEcCtD
Mefloquine—Diarrhoea—Capecitabine—esophageal cancer	0.000134	0.00211	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000132	0.0021	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—esophageal cancer	0.000131	0.00208	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—esophageal cancer	0.00013	0.00207	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—esophageal cancer	0.00013	0.00205	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—esophageal cancer	0.000129	0.00205	CcSEcCtD
Mefloquine—Dizziness—Capecitabine—esophageal cancer	0.000129	0.00204	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—esophageal cancer	0.000128	0.00202	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—esophageal cancer	0.000126	0.002	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000125	0.00199	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—esophageal cancer	0.000125	0.00198	CcSEcCtD
Mefloquine—Vomiting—Capecitabine—esophageal cancer	0.000124	0.00196	CcSEcCtD
Mefloquine—Rash—Capecitabine—esophageal cancer	0.000123	0.00195	CcSEcCtD
Mefloquine—Dermatitis—Capecitabine—esophageal cancer	0.000123	0.00195	CcSEcCtD
Mefloquine—Headache—Capecitabine—esophageal cancer	0.000122	0.00194	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—esophageal cancer	0.00012	0.0019	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000119	0.00188	CcSEcCtD
Mefloquine—Nausea—Capecitabine—esophageal cancer	0.000116	0.00184	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—esophageal cancer	0.000115	0.00183	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—esophageal cancer	0.000115	0.00182	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—esophageal cancer	0.000115	0.00182	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—esophageal cancer	0.000107	0.00169	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—esophageal cancer	0.000104	0.00165	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—esophageal cancer	0.000103	0.00163	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—esophageal cancer	9.94e-05	0.00157	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—esophageal cancer	9.61e-05	0.00152	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—esophageal cancer	9.24e-05	0.00146	CcSEcCtD
Mefloquine—Rash—Methotrexate—esophageal cancer	9.16e-05	0.00145	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—esophageal cancer	9.15e-05	0.00145	CcSEcCtD
Mefloquine—Headache—Methotrexate—esophageal cancer	9.1e-05	0.00144	CcSEcCtD
Mefloquine—Nausea—Methotrexate—esophageal cancer	8.63e-05	0.00137	CcSEcCtD
Mefloquine—ADORA2A—Signaling Pathways—PDE4D—esophageal cancer	3.06e-05	0.000177	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	3.05e-05	0.000176	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SST—esophageal cancer	3e-05	0.000173	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ALOX15—esophageal cancer	2.99e-05	0.000172	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GAPDH—esophageal cancer	2.95e-05	0.00017	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.94e-05	0.00017	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTO1—esophageal cancer	2.93e-05	0.000169	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—TPI1—esophageal cancer	2.93e-05	0.000169	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NOTCH3—esophageal cancer	2.93e-05	0.000169	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—GHRL—esophageal cancer	2.93e-05	0.000169	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CRABP1—esophageal cancer	2.92e-05	0.000169	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	2.91e-05	0.000168	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—GNG7—esophageal cancer	2.91e-05	0.000168	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FBXW7—esophageal cancer	2.88e-05	0.000166	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	2.87e-05	0.000166	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTO1—esophageal cancer	2.85e-05	0.000164	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—TPI1—esophageal cancer	2.85e-05	0.000164	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.85e-05	0.000164	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	2.85e-05	0.000164	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ALDOB—esophageal cancer	2.81e-05	0.000162	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GNG7—esophageal cancer	2.78e-05	0.00016	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ALDOB—esophageal cancer	2.73e-05	0.000158	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—XIAP—esophageal cancer	2.73e-05	0.000157	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PIK3CA—esophageal cancer	2.72e-05	0.000157	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GAPDH—esophageal cancer	2.71e-05	0.000156	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CRABP1—esophageal cancer	2.68e-05	0.000155	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—PIK3CA—esophageal cancer	2.67e-05	0.000154	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GAPDH—esophageal cancer	2.63e-05	0.000152	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NOTCH2—esophageal cancer	2.62e-05	0.000151	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CRABP1—esophageal cancer	2.61e-05	0.00015	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ALDH2—esophageal cancer	2.6e-05	0.00015	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	2.58e-05	0.000149	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CTNNA1—esophageal cancer	2.58e-05	0.000149	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL2—esophageal cancer	2.56e-05	0.000148	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	2.55e-05	0.000147	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GNG7—esophageal cancer	2.55e-05	0.000147	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	2.54e-05	0.000147	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC52A3—esophageal cancer	2.54e-05	0.000146	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—BLVRB—esophageal cancer	2.54e-05	0.000146	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GNG7—esophageal cancer	2.48e-05	0.000143	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GSTT1—esophageal cancer	2.48e-05	0.000143	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP2A6—esophageal cancer	2.45e-05	0.000141	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.44e-05	0.000141	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PSME2—esophageal cancer	2.39e-05	0.000138	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PSME1—esophageal cancer	2.39e-05	0.000138	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ALDH2—esophageal cancer	2.39e-05	0.000138	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	2.39e-05	0.000138	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—BLVRB—esophageal cancer	2.39e-05	0.000138	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ANXA1—esophageal cancer	2.38e-05	0.000138	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TGFBR2—esophageal cancer	2.33e-05	0.000134	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ALDH2—esophageal cancer	2.32e-05	0.000134	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ENO1—esophageal cancer	2.32e-05	0.000134	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS1—esophageal cancer	2.32e-05	0.000134	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SST—esophageal cancer	2.32e-05	0.000134	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PSME2—esophageal cancer	2.29e-05	0.000132	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PSME1—esophageal cancer	2.29e-05	0.000132	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTT1—esophageal cancer	2.28e-05	0.000131	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—GHRL—esophageal cancer	2.26e-05	0.00013	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOTCH3—esophageal cancer	2.26e-05	0.00013	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CYP2A6—esophageal cancer	2.25e-05	0.00013	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.24e-05	0.000129	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FBXW7—esophageal cancer	2.22e-05	0.000128	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTT1—esophageal cancer	2.21e-05	0.000128	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SMAD4—esophageal cancer	2.2e-05	0.000127	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	2.19e-05	0.000126	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP2A6—esophageal cancer	2.18e-05	0.000126	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.18e-05	0.000126	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC10A2—esophageal cancer	2.16e-05	0.000125	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CA1—esophageal cancer	2.16e-05	0.000125	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ENO1—esophageal cancer	2.13e-05	0.000123	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS1—esophageal cancer	2.13e-05	0.000123	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	2.13e-05	0.000123	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PSME1—esophageal cancer	2.1e-05	0.000121	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PSME2—esophageal cancer	2.1e-05	0.000121	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	2.08e-05	0.00012	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ENO1—esophageal cancer	2.07e-05	0.000119	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS1—esophageal cancer	2.07e-05	0.000119	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PSME2—esophageal cancer	2.04e-05	0.000118	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PSME1—esophageal cancer	2.04e-05	0.000118	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	2.03e-05	0.000117	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CA1—esophageal cancer	2.03e-05	0.000117	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOTCH2—esophageal cancer	2.03e-05	0.000117	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2e-05	0.000115	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CA2—esophageal cancer	1.97e-05	0.000114	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP1B1—esophageal cancer	1.97e-05	0.000114	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.88e-05	0.000109	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CA2—esophageal cancer	1.86e-05	0.000107	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP19A1—esophageal cancer	1.86e-05	0.000107	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.83e-05	0.000106	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PLCE1—esophageal cancer	1.83e-05	0.000106	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ADH7—esophageal cancer	1.83e-05	0.000106	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.82e-05	0.000105	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CYP1B1—esophageal cancer	1.81e-05	0.000105	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HIF1A—esophageal cancer	1.8e-05	0.000104	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TGFBR2—esophageal cancer	1.8e-05	0.000104	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.78e-05	0.000103	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP1B1—esophageal cancer	1.76e-05	0.000102	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.73e-05	9.99e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PLCE1—esophageal cancer	1.73e-05	9.98e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ADH7—esophageal cancer	1.73e-05	9.98e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KDR—esophageal cancer	1.72e-05	9.95e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SMAD4—esophageal cancer	1.7e-05	9.82e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—HMOX1—esophageal cancer	1.69e-05	9.77e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.66e-05	9.59e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP19A1—esophageal cancer	1.65e-05	9.55e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ABCB1—esophageal cancer	1.62e-05	9.38e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NOTCH1—esophageal cancer	1.62e-05	9.37e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ADH1B—esophageal cancer	1.61e-05	9.28e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.57e-05	9.08e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	1.56e-05	9.02e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—BLVRB—esophageal cancer	1.56e-05	9.02e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—HMOX1—esophageal cancer	1.56e-05	8.98e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TYMP—esophageal cancer	1.54e-05	8.87e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.53e-05	8.81e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ADH1B—esophageal cancer	1.52e-05	8.75e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—HMOX1—esophageal cancer	1.51e-05	8.72e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.51e-05	8.71e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.5e-05	8.63e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ABCB1—esophageal cancer	1.49e-05	8.62e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.48e-05	8.55e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.48e-05	8.52e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CREBBP—esophageal cancer	1.47e-05	8.5e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALOX15—esophageal cancer	1.46e-05	8.41e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ABCB1—esophageal cancer	1.45e-05	8.37e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TYMP—esophageal cancer	1.45e-05	8.36e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—EGFR—esophageal cancer	1.45e-05	8.35e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	1.41e-05	8.13e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HIF1A—esophageal cancer	1.39e-05	8.03e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TPI1—esophageal cancer	1.39e-05	8.02e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTO1—esophageal cancer	1.39e-05	8.02e-05	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.38e-05	7.98e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.37e-05	7.93e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALDOB—esophageal cancer	1.33e-05	7.69e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KDR—esophageal cancer	1.33e-05	7.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.33e-05	7.67e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CA1—esophageal cancer	1.33e-05	7.67e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NOS3—esophageal cancer	1.32e-05	7.61e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TPI1—esophageal cancer	1.31e-05	7.56e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.31e-05	7.56e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GAPDH—esophageal cancer	1.28e-05	7.41e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.28e-05	7.39e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CRABP1—esophageal cancer	1.27e-05	7.34e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.26e-05	7.25e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CA—esophageal cancer	1.26e-05	7.25e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOTCH1—esophageal cancer	1.25e-05	7.24e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.24e-05	7.15e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ERBB2—esophageal cancer	1.23e-05	7.12e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.23e-05	7.09e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CA2—esophageal cancer	1.22e-05	7.02e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GNG7—esophageal cancer	1.21e-05	6.98e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GAPDH—esophageal cancer	1.21e-05	6.98e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CRABP1—esophageal cancer	1.2e-05	6.92e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GNG7—esophageal cancer	1.14e-05	6.58e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CREBBP—esophageal cancer	1.14e-05	6.56e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALDH2—esophageal cancer	1.13e-05	6.54e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ADH7—esophageal cancer	1.13e-05	6.52e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PLCE1—esophageal cancer	1.13e-05	6.52e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.13e-05	6.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—esophageal cancer	1.12e-05	6.45e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.1e-05	6.33e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—esophageal cancer	1.09e-05	6.29e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CREBBP—esophageal cancer	1.09e-05	6.27e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTT1—esophageal cancer	1.08e-05	6.22e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.07e-05	6.16e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	1.07e-05	6.16e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.07e-05	6.15e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1A—esophageal cancer	1.05e-05	6.08e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOS3—esophageal cancer	1.02e-05	5.88e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.02e-05	5.86e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS1—esophageal cancer	1.01e-05	5.83e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO1—esophageal cancer	1.01e-05	5.83e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.01e-05	5.83e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1e-05	5.8e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EP300—esophageal cancer	1e-05	5.79e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CREBBP—esophageal cancer	9.98e-06	5.76e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PSME2—esophageal cancer	9.95e-06	5.74e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PSME1—esophageal cancer	9.95e-06	5.74e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ADH1B—esophageal cancer	9.91e-06	5.72e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NOS3—esophageal cancer	9.72e-06	5.61e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—esophageal cancer	9.7e-06	5.6e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CREBBP—esophageal cancer	9.69e-06	5.59e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—esophageal cancer	9.52e-06	5.5e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO1—esophageal cancer	9.52e-06	5.49e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS1—esophageal cancer	9.52e-06	5.49e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TYMP—esophageal cancer	9.47e-06	5.47e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PSME1—esophageal cancer	9.38e-06	5.41e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PSME2—esophageal cancer	9.38e-06	5.41e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	9.21e-06	5.32e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALOX15—esophageal cancer	8.98e-06	5.18e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NOS3—esophageal cancer	8.93e-06	5.16e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—esophageal cancer	8.89e-06	5.13e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—esophageal cancer	8.74e-06	5.04e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NOS3—esophageal cancer	8.67e-06	5.01e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1B1—esophageal cancer	8.59e-06	4.96e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTO1—esophageal cancer	8.56e-06	4.94e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TPI1—esophageal cancer	8.56e-06	4.94e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—esophageal cancer	8.55e-06	4.93e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—esophageal cancer	8.41e-06	4.86e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALDOB—esophageal cancer	8.21e-06	4.74e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—esophageal cancer	8.17e-06	4.72e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1A—esophageal cancer	8.14e-06	4.7e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	8.09e-06	4.67e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP19A1—esophageal cancer	8.07e-06	4.66e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—esophageal cancer	7.93e-06	4.58e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GAPDH—esophageal cancer	7.9e-06	4.56e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CRABP1—esophageal cancer	7.83e-06	4.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EP300—esophageal cancer	7.74e-06	4.47e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	7.61e-06	4.39e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GNG7—esophageal cancer	7.45e-06	4.3e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—esophageal cancer	7.42e-06	4.28e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—EP300—esophageal cancer	7.4e-06	4.27e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HMOX1—esophageal cancer	7.37e-06	4.25e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—esophageal cancer	7.18e-06	4.14e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALDH2—esophageal cancer	6.98e-06	4.03e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HMOX1—esophageal cancer	6.94e-06	4.01e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—EP300—esophageal cancer	6.8e-06	3.92e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—esophageal cancer	6.75e-06	3.89e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCB1—esophageal cancer	6.66e-06	3.85e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTT1—esophageal cancer	6.64e-06	3.83e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—esophageal cancer	6.6e-06	3.81e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—EP300—esophageal cancer	6.6e-06	3.81e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	6.56e-06	3.79e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO1—esophageal cancer	6.22e-06	3.59e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS1—esophageal cancer	6.22e-06	3.59e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PSME1—esophageal cancer	6.13e-06	3.54e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PSME2—esophageal cancer	6.13e-06	3.54e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—esophageal cancer	5.73e-06	3.31e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—esophageal cancer	5.54e-06	3.2e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—esophageal cancer	5.47e-06	3.16e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	5.29e-06	3.05e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—esophageal cancer	5.03e-06	2.9e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.97e-06	2.87e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—esophageal cancer	4.88e-06	2.82e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CREBBP—esophageal cancer	4.73e-06	2.73e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HMOX1—esophageal cancer	4.54e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CREBBP—esophageal cancer	4.45e-06	2.57e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCB1—esophageal cancer	4.36e-06	2.52e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NOS3—esophageal cancer	4.23e-06	2.44e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.99e-06	2.3e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—esophageal cancer	3.87e-06	2.23e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—esophageal cancer	3.65e-06	2.11e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—EP300—esophageal cancer	3.22e-06	1.86e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—EP300—esophageal cancer	3.03e-06	1.75e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.91e-06	1.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.61e-06	1.5e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.38e-06	1.38e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—esophageal cancer	2.38e-06	1.37e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	2.24e-06	1.3e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—EP300—esophageal cancer	1.98e-06	1.14e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.47e-06	8.47e-06	CbGpPWpGaD
